Annals of Internal Medicine, tip sheet, July 2, 2002

July 01, 2002

Annals of Internal Medicine is published by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), an organization of more than 115,000 internal medicine physicians and medical students. The following highlights are not intended to substitute for articles as sources of information. For an embargoed fax of an article, call 1-800-523-1546, ext. 2656 or 215-351-2656.

USPSTF Recommendations on Using Drugs to Prevent Breast Cancer

Recent evidence indicates that drugs that interfere with the action of estrogen on breast tissue can lower the risk that breast cancer will occur in women at high risk. The U.S. Preventive Services Task Force (USPSTF) considered this evidence in its recommendation that women at low or average risk for breast cancer avoid taking drugs such as tamoxifen or raloxifene to prevent breast cancer. The USPSTF says that women at high risk for breast cancer and at low risk for serious side effects from the drugs should talk with their doctors about the risks and benefits of taking the drugs to prevent breast cancer. The recommendations and a background summary of the evidence for the recommendations are published in today's Annals of Internal Medicine (Clinical Guidelines: Recommendations, p. 56; Summary of Evidence, p. 59). An editorial says that the recommendation to discuss drug therapy with selected patients "raises more questions for clinicians than it answers," (Editorial, p. 52). The writers say that current medical research on this issue is incomplete, and that both women and their physicians "need to understand the limits of what we know and what we can control about the future."

Should Blood Enzyme Levels for Liver Disease Be Changed?

Measuring blood levels of the enzyme, serum alanine aminotransferase (ALT), is the most common way to test for liver disease. Blood enzyme levels above a certain value indicate liver disease. A new study recommends lowering the current upper limit of normal blood ALT levels (Article, p. 1). Researchers suspected that the studies that set the currently accepted normal levels included patients with liver disease that could not be detected when the studies were done. They studied 6,835 first-time blood donors who tested negative for hepatitis C virus (HCV). Defining the "normal" level of ALT as the mean value of ALT levels of those at lowest risk for liver disease, the researchers found a substantially lower value for the upper end of the range of normal ALT than laboratories currently use. They recommend using the new, lower level to define ALT levels that would indicate liver disease.

An editorial says that the study "was carefully done and the results unquestionably correct" (Editorial, p. 49). But using the new normal limits for ALT to decide who has liver disease would cause many millions of patients to be identified with "abnormal" ALT levels. Evaluting these people for liver disease could "overwhelm the health care system," the writer says. Most of these people would be found to have liver diseases that are not serious and seldom progress to serious liver disease.

Annals of Internal Medicine Celebrates 75 Years

Annals of Internal Medicine celebrates its 75th anniversary with a review of highlights of its most recent 25 years (History of Medicine, p. 34). An accompanying editorial surveys topics of concern to all medical journals, such as research design, editorial practices, standardization among journals, popularization of content and format, cost, and accessibility to researchers and the public. The editorial writer is not sure that medical journals have done all they could to play their part in the stunning progress in the science of medicine over the past 25 years (Editorial, p. 46).
-end-


American College of Physicians

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.